Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

65P - Durvalumab combined with chemotherapy and radiotherapy in patients with oligometastatic non-small cell lung cancer (SABRcure)

Date

22 Mar 2024

Session

Poster Display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Qiwen Li

Citation

Annals of Oncology (2024) 9 (suppl_3): 1-53. 10.1016/esmoop/esmoop102569

Authors

Q. Li1, H. Ma2, R. Zheng3, Y. Ling4, L. Cai1, Y. Zhang1, Y. Xu5, Y. Bao6, F. Peng7, H. Chen8, A. Liu9, M. Chen1

Author affiliations

  • 1 Sun Yat-Sen University Cancer Center, Guangzhou/CN
  • 2 Zhejiang Cancer Hospital, Hangzhou/CN
  • 3 Sun Yat-Sen University Cancer Center, Guangzhou, Guangzhou/CN
  • 4 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou/CN
  • 5 Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou/CN
  • 6 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN
  • 7 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou/CN
  • 8 Affiliated Hospital of Guangdong Medical College, Zhanjiang/CN
  • 9 2nd Affiliated Hospital of Nanchang University, Nanchang/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 65P

Background

Immunotherapy plus chemotherapy is the standard of care for metastatic non-small cell lung cancer (NSCLC). Radiotherapy (RT) achieved prolonged progression-free survival (PFS) and overall survival (OS) in well selected oligometastatic NSCLC patients. However, the value of additional RT to immuno-chemotherapy remains unclear.

Methods

SABRcure is a multi-center phase II study evaluating the efficacy and safety of durvalumab combined with chemotherapy and RT in patients with oligometastatic EGFR/ALKwt NSCLC. Patients received durvalumab and chemotherapy for 4 cycles, followed by RT to all lesion, and durvalumab monotherapy until disease progression, or intolerance, or up to 24 months(m). Stereotactic ablative body RT (SABR) and definitive RT was performed if feasible. The primary endpoint was PFS per RECIST v1.1. Secondary end points were objective response rate (ORR), OS and safety.

Results

Between Sep 2021 and Apr 2023, 35 patients from 5 hospitals were enrolled (median age 65 years, 57.1% adenocarcinoma). There were 28 (80%) patients received RT and 23 (65.7%) received SABR. As of December 10th, 2023, 11 patients were still on treatment with durvalumab. With median follow up of 15.7 m, median PFS was 10.4 m (95% CI 4.4, NE). One-year OS rate was 73.6% (95% CI 55.3%, 85.3%). ORR was 71.9%. Median PFS was 18.69 m (7.23, NE) and 24.3 m (7.6, NE) in patients with RT and SABR, respectively. More subgroup analyses were described in the table. Adverse events (AE) ≥grade 3 were reported in 57.1% (20/35). SAE was reported in 45.7% (16/35) and imAE occurred in 34.3% (12/35). Table: 65P

Population (n) Median PFS (95% CI) (m) 1-year PFS rate % (95% CI)
FAS (35) 10.4 (4.4, NE) 43.0 (25.1, 59.0)
With RT (28) 18.69 (7.23, NE) 52.1 (30.8, 69.8)
With SABR (23) 24.3 (7.6, NE) 55.8 (31.7, 74.3)
With bone metastasis (18) 10.4 (4.3, NE) 38.6 (13.5, 63.6)
With visceral metastasis (17) 7.2 (3.5, NE) 37.6 (15.5, 59.9)

Conclusions

In oligometastatic NSCLC, the combination of durvalumab, chemotherapy and RT is effective and tolerable. Patients without disease progression after upfront systematic therapy and receive RT/SABR have longer PFS, indicating that RT/SABR may be the key to improve efficacy.

Clinical trial identification

NCT04255836.

Legal entity responsible for the study

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).

Funding

AstraZeneca China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.